Design and synthesis of the cb1 selective cannabinoid antagonist AM281: A potential human SPECT ligand

AAPS Journal

Volumn 1, Issue 2, 1999, Pages

  Lan, Ruoxi ^a   Lu, Qian ^a   Fan, Pusheng ^a   Gatley, John ^b   Volkow, Nora D ^b   Fernando, Susanthi R ^c   Pertwee, Roger ^c   Makriyannis, Alexandras ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

AM281; Cannabinoid cb1 receptor; Cannabinoid receptor antagonist; Cb1 selective ligand; Spect image

Indexed keywords

EID: 53149102837     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Martin BR. Cellular effects of cannabinoids. Pharmacol Rev. 1986;38:45-74.
2. Devane WA, Dysarz FA 3d, Johnson MR, Melvin LS, Hewlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988; 34:605-613.
3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (London) 1993;365:61-65.
4. Earth F, Casellas P, Congy C, Martinez S, Rinaldi M, AnneArchard G. Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present. US Patent 5,624,941 Apr. 29, 1997.
5. Rinaldi-Carmona M, Earth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Breliere JC, Le Fur G. SR141716A, A potent and selective antagonist of the brain cannabinoid receptor. FEES Lett. 1994;350:240-244.
6. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Breliere JC, Le Fur G. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 1995;56:1941-1947.
7. Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Le Fur G, Caput D, Ferrara P. Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem. 1996;271:6941-6946.
8. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Earth F, Bachy A, Breliere JC, Soubrié P, Le Fur G. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. 1996;58:1239-1247.
9. Galley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A. 123ILabeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB! receptors. Fur J Pharmacol. 1996;307:331-338.
10. Lan R, Galley SJ, Makriyannis A. Preparation of iodine-123 labeled AM251: a potential SPECT radioligand for ihe brain cannabinoid CB1 receptor. J Label Compds Radiopharma 1996;38:875-881.
11. Galley SJ, Lan R, Pyall B, Gifford AN, Volkow ND, Makriyannis A. Binding of ihe non-classical cannabinoid CP 55,940, and ihe diarylpyrazole AM251 lo rodenl brain cannabinoid receptors. Life Sci. 1997;61:PL191-197.
12. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, DeCosla BR, Rice KC. Cannabinoid receptor localization in brain. Proc Nail Acad Sci. 1990;87:1932-1936.
13. Herkenham M, Lynn AB, Johnson MR, Melvin LS, DeCosla BR, Rice KC. Characterization and localization of cannabinoid receptors in ral brain: a quantitative in vitro auloradiographic study. J Neurosci. 1991;ll:563-583.
14. Galley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyall B, Dewey SL, Makriyannis A. Imaging ihe brain marijuana receptor: Developmenl of a radioligand lhal binds lo cannabinoid CB1 receptors in vivo. J Neurochem. 1998; 70:417-23.
15. Hanson RN, El-Wakil H. Eleclrophilic deslannylalion: slereospecific inlroduclion of eleclrophiles al ihe 21 position of (17a)-19-Norpregna-l,3,5(10),20-lelraene-3-17β-diols. J Org Chem. 1987;52:3687-3688.
16. Perlwee, RG, Fernando, SR, Nash, JE, Coulis, AA. Further evidence for ihe presence of cannabinoid CB 1 receptors in guinea-pig small intestine. BrJ Pharmacol. 1996;118:2199-2205.
17. Gifford AN, Tang Y, Galley SJ, Volkow ND, Lan R, Makriyannis A. Effecl of ihe cannabinoid receptor SPECT agenl, AM 281, on hippocampal acelylcholine release from ral brain slices. Neurosci Lett. 1997;238:84-86.
18. Drake DJ, Jensen RS, Busch-Pelerson J, Kawakami JK, Fernandez-Garcia MC, Fan P, Makriyannis A, Tius MA. Classical/nonclassical hydrid cannabinoids: soulhern aliphatic chainfunclionalized C-6β melhyl, elhyl, and propyl analogues. J Med Chem. 1998;41:3596-3608.
19. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37:1889-1893.
20. Dodd PR, Hardy JA, Oakley AL, Ldwardson JA, Perry LK, Delaunoy JP. A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res. 1981;226:107118.
21. Charalambous A, Quo Y, Houston DB, Hewlett AC, Compton DR, Martin BR, Makriyannis A. 5'-Azido-A8-THC: a novel photoaffinity label for the cannabinoid receptor. J Med Chem. 1992;35:3076-3079.
22. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K() and the concentration of inhibitor which causes 50 per cent (IC50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
23. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig Myenteric plexus. BrJ Pharmacol. 1997;21:1557-1566.
24. Tallarida RJ, Cowan A, Adler MW. pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 1979;25:637-654.
25. Colquhoun D. Lectures on Biostatistics. Oxford: Oxford University Press; 1971.